Cellulitis

ABSSSI (cellulitis) patientABSSSI (cellulitis) patient
Not an actual patient

Patients like Rich may be considered an appropriate
candidate for SIVEXTRO

Diagnosis: ABSSSI (cellulitis)

45-year-old male with infection site on lower leg

Patient profile:

  • 45-year-old white male
  • 5'5", 220 lbs, BMI of 36.6 kg/m2

Medical history:

  • Type 2 diabetes, obesity

Drug allergies:

  • None reported

Current presentation:

  • Redness, swelling, and tenderness at the infection site on left lower leg

Relevant Acute Findings

Vital signs:

  • Temp: 98.6°F; RR: 15; HR: 80

Physical examination:

  • Lesion surface area involving left lower leg that measures 276 cm2 with localized warmth,
    tenderness, edema, and erythema that is well-demarcated
  • No evidence of drainage
  • Local lymph node tenderness

Laboratory test results:

  • WBC count: 12,000 x 103/mL with left shift

Diagnosis:

  • ABSSSI—diffuse cellulitis

Next steps:

  • Initiate empiric antimicrobial therapy
ABSSSI (cellulitis) patientABSSSI (cellulitis) patient
Not an actual patient

Patients like Brandon may be considered an appropriate
candidate for SIVEXTRO

Diagnosis: ABSSSI (cellulitis)

27-year-old male with abrasion on arm from hiking

Patient profile:

  • 27-year-old white male
  • 6'2", 181 lbs, BMI of 23.2 kg/m2

Medical history:

  • No significant medical history

Drug allergies:

  • Sulfa medications

Current presentation:

  • Abrasion on left arm from hiking
  • Mild swelling and pain at the infection site

Relevant Acute Findings

Vital signs:

  • Temp: 98.1°F; RR: 16; HR: 90

Physical examination:

  • Lesion surface area involving left arm that measures 150 cm2
  • Localized pain, edema, induration, and erythema that is well-demarcated

Laboratory test results:

  • WBC count: 11,000 x 103/mL

Diagnosis:

  • ABSSSI—diffuse cellulitis

Next steps:

  • Initiate empiric antimicrobial therapy

ABSSSI=acute bacterial skin and skin structure infections; BMI=body mass index; HR=heart rate; RR=respiratory rate; Temp=temperature; WBC=white blood cell.

ABSSSI=acute bacterial skin and skin structure infections.
ABSSSI=acute bacterial skin and skin structure infections; IV=intravenous.
ABSSSI=acute bacterial skin and skin structure infections; MRSA=methicillin-resistant Staphylococcus aureus; MSSA=methicillin-susceptible Staphylococcus aureus.
ABSSSI=acute bacterial skin and skin structure infections.
1. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559-569.
ABSSSI=acute bacterial skin and skin structure infections; IV=intravenous.
1. Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696-705.
ABSSSI=acute bacterial skin and skin structure infections.
1. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559-569.
2. Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696-705.
ABSSSI=acute bacterial skin and skin structure infections.
1. Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508-519.
2. Lane S, Johnston K, Sulham KA, et al. Identification of patient characteristics influencing setting of care decisions for patients with acute bacterial skin and skin structure infections: Results of a discrete choice experiment. Clin Ther. 2016;38(3):531-544.
Selected Important Safety Information

Patients with neutropenia: The safety and efficacy of SIVEXTRO® (tedizolid phosphate) in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes. Alternative therapies should be considered when treating patients with neutropenia.

Clostridium difficile–associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including SIVEXTRO. Evaluate all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, antibacterial use not directed against C. difficile should be discontinued, if possible.

Development of drug-resistant bacteria: Prescribing SIVEXTRO in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse reactions: The most common adverse reactions for SIVEXTRO are nausea (8%), headache (6%), diarrhea (4%), vomiting (3%), and dizziness (2%).

Drug interactions with BCRP substrates: SIVEXTRO (when administered orally) can increase the plasma concentrations of orally administered Breast Cancer Resistance Protein (BCRP) substrates and the potential for adverse reactions. Monitor for adverse reactions related to the concomitant BCRP substrates if coadministration cannot be avoided.

Before prescribing SIVEXTRO, please read the accompanying Prescribing Information.

MULT-1044371-0307 07/15

Please orient your device to the portrait position to return to the site.

Indication and Usage

Indication: SIVEXTRO® (tedizolid phosphate) is an oxazolidinone-class antibacterial indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis.

Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Expand [+] Collapse [–]
Expand [+] Collapse [–]
Selected Important Safety Information

Patients with neutropenia: The safety and efficacy of SIVEXTRO® (tedizolid phosphate) in patients with neutropenia (neutrophil counts <1000 cells/mm3) have not been adequately evaluated. In an animal model of infection, the antibacterial activity of SIVEXTRO was reduced in the absence of granulocytes. Alternative therapies should be considered when treating patients with neutropenia.

Clostridium difficile–associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, has been reported with nearly all systemic antibacterial agents, including SIVEXTRO. Evaluate all patients who present with diarrhea following antibiotic use. Careful medical history is necessary because CDAD has been reported to occur more than two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, antibacterial use not directed against C. difficile should be discontinued, if possible.

Development of drug-resistant bacteria: Prescribing SIVEXTRO in the absence of a proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Adverse reactions: The most common adverse reactions for SIVEXTRO are nausea (8%), headache (6%), diarrhea (4%), vomiting (3%), and dizziness (2%).

Drug interactions with BCRP substrates: SIVEXTRO (when administered orally) can increase the plasma concentrations of orally administered Breast Cancer Resistance Protein (BCRP) substrates and the potential for adverse reactions. Monitor for adverse reactions related to the concomitant BCRP substrates if coadministration cannot be avoided.

Before prescribing SIVEXTRO, please read the accompanying Prescribing Information.